The Technical Analyst
CURE Pharmaceutical [CURR]
Exchange: PNK Industry: Drug Manufacturers
CURE Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
-8.00% $0.115
America/New_York / 8 aug 2023 @ 15:04
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.21 mill |
| EPS: | -0.220 |
| P/E: | -0.523 |
| Earnings Date: | Sep 01, 2022 |
| SharesOutstanding: | 71.38 mill |
| Avg Daily Volume: | 0.0177 mill |
| RATING 2023-09-05 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.523 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.523 | industry: PE -6.21 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0770 - 0.143 ( +/- 30.00%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-09-23 | Salkind Gene Z | Buy | 117 647 | Common Stock |
| 2021-09-23 | Salkind Gene Z | Buy | 117 647 | Restricted Stock Unit |
| 2023-08-17 | Salkind Gene Z | Buy | 186 364 | Restricted Stock Unit |
| 2023-08-17 | Bagg Gerald | Buy | 186 364 | Restricted Stock Unit |
| 2023-08-17 | Costantino Robert J | Buy | 186 364 | Restricted Stock Unit |
| INSIDER POWER |
|---|
| 100.00 |
| Last 90 transactions |
| Buy: 9 233 498 | Sell: 208 150 |
Forecast:
01:40 - $0.0930
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.115 (-8.00% ) |
| Volume | 0.0013 mill |
| Avg. Vol. | 0.0177 mill |
| % of Avg. Vol | 7.08 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CURR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CURR
CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company's pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It also sells various wellness products under its distribution partners' brands. In addition, the company develops 50,000IU and Vitamin D3 OTF for oral administration. It has a licensing agreement with Canopy Growth Corporation. The company was founded in 2011 and is headquartered in Oxnard, California.
Latest Press Releases
2023-08-08 15:25:00 - Press Release
Avenir Wellness Solutions Announces New Ticker Symbol As Final Part Of Exciting New Brand Identity
New branding reflects company's commitment to the future of wellness sherman oaks, ca / accesswire / august 8, 2023 / avenir wellness solutions, inc. (otc pink:curr) ("avenir" or the "company"), a proprietary broad platform and wellness technology company, today announced that it has received regulatory approval to officially change its ticker symbol from "curr" to "avrw" effective at the stock market opening on august 9, 2023. the ticker symbol change follows the corporate name change to "avenir wellness solutions, inc." in october 2022.
2023-04-26 15:15:00 - Press Release
Avenir Wellness Solutions (otcqb:curr) To Present At The Planet Microcap Showcase - Live Webcast Available
Presentation today at 1:30pm pacific time (4:30 pm eastern time) sherman oaks, ca / accesswire / april 26, 2023 / avenir wellness solutions, inc. ("avenir wellness") (otcqb:curr), a proprietary broad platform technology and wellness company, announced today that it will be presenting at the planet microcap showcase today wednesday, april 26, 2023, at 1:30 pm pacific time (4:30 pm eastern time). the company's ceo, nancy duitch, will be presenting.
2022-11-10 19:30:00 - Press Release
Avenir Wellness Solutions To Present At Investor Summit Group's Q4 Conference
Sherman oaks, california--(newsfile corp. - november 10, 2022) - avenir wellness solutions, inc. (f/k/a cure pharmaceutical holding corp.) (otcqb: curr) today announced that ceo nancy duitch will be attending the q4 investor summit live in nyc at the sheraton times square.
2022-10-24 07:30:00 - Press Release
Cure Pharmaceutical Holding To Present At The Ld Micro Main Event Xv
Presentation on tuesday, october 25 at 12:30 pm pacific time (3:30 pm eastern)oxnard, california--(newsfile corp. - october 24, 2022) - cure pharmaceutical holding corp. (otcqb: curr) ("cure"), a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems, announced today that it will be presenting at the 12th annual invitational on tuesday october 25 at 12:30 pm pacific time (3:30 pm eastern) at the luxe sunset boulevard hotel. nancy duitch, ceo will be giving the presentation.
2021-06-15 08:15:00 - Press Release
Cure Pharmaceutical To Present At H.c. Wainwright 2021 Psychedelics In Psychiatry And Beyond Virtual Conference
Oxnard, calif.--(business wire)--cure pharmaceutical holding corp. (otc: curr), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its chief business officer jonathan berlent will participate in a virtual presentation at the h.c. wainwright psychedelics in psychiatry and beyond virtual conference on thursday, june 17. "the potential therapeutic benefits of psychedelics to treat m
Latest News
2023-04-26 15:15:00 - Accesswire
Avenir Wellness Solutions (OTCQB:CURR) to Present at the Planet MicroCap Showcase - Live Webcast Available
Presentation TODAY at 1:30PM Pacific Time (4:30 PM Eastern Time) SHERMAN OAKS, CA / ACCESSWIRE / April 26, 2023 / Avenir Wellness Solutions, Inc. ("Avenir Wellness") (OTCQB:CURR), a proprietary broad platform technology and wellness company, announced today that it will be presenting at the Planet MicroCap Showcase TODAY Wednesday, April 26, 2023, at 1:30 PM Pacific Time (4:30 PM Eastern Time). The Company's CEO, Nancy Duitch, will be presenting.
2022-11-10 19:30:00 - Newsfile Corp
Avenir Wellness Solutions to Present at Investor Summit Group's Q4 Conference
Sherman Oaks, California--(Newsfile Corp. - November 10, 2022) - Avenir Wellness Solutions, Inc. (f/k/a CURE Pharmaceutical Holding Corp.) (OTCQB: CURR) today announced that CEO Nancy Duitch will be attending the Q4 Investor Summit live in NYC at the Sheraton Times Square.
2022-10-24 07:30:00 - Newsfile Corp
Cure Pharmaceutical Holding to Present at the LD Micro Main Event XV
Presentation on Tuesday, October 25 at 12:30 PM Pacific Time (3:30 PM Eastern)Oxnard, California--(Newsfile Corp. - October 24, 2022) - Cure Pharmaceutical Holding Corp. (OTCQB: CURR) ("CURE"), a broad wellness platform technology company that develops proprietary wellness, nutraceutical, and topical delivery systems, announced today that it will be presenting at the 12th annual Invitational on Tuesday October 25 at 12:30 PM Pacific Time (3:30 PM Eastern) at the Luxe Sunset Boulevard Hotel. Nancy Duitch, CEO will be giving the presentation.
2021-08-18 09:27:30 - Benzinga
CURE Pharmaceutical Q2 2021 Revenue Spikes 700% After Increased Sales From Seba Labs Products Including A CVS Deal
Pharmaceutical company CURE Pharmaceutical Holding Corp. (OTC:CURR) announced earnings results on Tuesday for the quarter ended June 30, revealing revenue of $2.1 million. That's a year-over-year increase of 700%.
2021-06-15 08:15:00 - Business Wire
CURE Pharmaceutical to Present at H.C. Wainwright 2021 Psychedelics in Psychiatry and Beyond Virtual Conference
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company in the pharmaceutical and health & wellness markets, announced today that its Chief Business Officer Jonathan Berlent will participate in a virtual presentation at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on Thursday, June 17. "The potential therapeutic benefits of psychedelics to treat m
2021-06-11 15:48:45 - Benzinga
Federally Compliant Medical Cannabis In The US? One Company Is Doing It
CURE Pharmaceutical (OTC:CURR) has signed an agreement with Biopharmaceutical Research Company (BRC) to produce federally compliant medical cannabis, CBD and THC products. BRC will provide the cannabinoid ingredients and CURE will use them to begin the development of CBD and THC oral thin films for CURE's clinical studies targeted at advancing veteran health.
2021-06-10 08:15:00 - Business Wire
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films and Conduct Clinical Studies Targeting Veteran Health
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has signed a partnership agreement with Biopharmaceutical Research Company, (BRC), an active Drug Enforcement Administration (DEA) license holder, to produce federally-compliant cannabis-based medical products. Currently, CURE uses its Schedule 1 DEA license for the development of Cannabis (THC) oral film products and othe
2021-05-17 09:15:00 - Business Wire
CURE Pharmaceutical First Quarter Revenue Quadruples to $1.5 million; Company Expands Clinical Pipeline to Include Psychedelics
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (OTC: CURR), a vertically integrated drug delivery and product development company, reported its financial results and provided an operational update for the first quarter ended March 31, 2021. First Quarter 2021 and subsequent weeks highlights: Total revenue rose more than 400% to $1.5 million compared with a year ago and gross profit rose in line with revenue growth. Received approval for an Investigational New Drug (IND) appl
2021-05-13 08:15:00 - Business Wire
CURE Pharmaceutical Receives ISO Certification for Laboratory and Manufacturing Facility
LOS ANGELES--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has secured International Organization for Standardization (ISO) 9001 certification for its Oxnard, Calif., manufacturing and research facility. ISO 9001 certification recognizes excellence in quality management standards of an organization that places an emphasis on its customers, the motivation and
2021-03-16 08:45:00 - Business Wire
CURE Pharmaceutical Launches Psychedelic Oral Film Program Targeting the Treatment of Mental Health Disorders
OXNARD, Calif.--(BUSINESS WIRE)--CURE Pharmaceutical Holding Corp. (“CURE” or the “Company”) (OTC: CURR), a vertically integrated drug delivery and product development company, announced today that it has launched a new initiative for the clinical development of psychedelic compounds such as psilocybin, LSD, and MDMA for the treatment of various mental health disorders. Utilizing CURE's patented oral film platform CUREfilm® for precision dosing, the company intends to optimize the absorption an